May 14, 2024 | Press Releases
– Gained alignment with U.S. Food and Drug Administration (FDA) on brilaroxazine clinical trials for New Drug Application (NDA) submission in schizophrenia – – Registrational RECOVER-2 trial expected to initiate Q2 2024; topline data expected Q3 2025...
May 13, 2024 | Press Releases
CUPERTINO, Calif., May 13, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
May 9, 2024 | Press Releases
CUPERTINO, Calif., May 09, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central...
Apr 15, 2024 | Press Releases
– RECOVER-1 Phase 3 global trial successfully met all primary and secondary endpoints with statistically significant reductions across all major symptom domains in schizophrenia – – Initiation of registrational RECOVER-2 trial expected in the second...
Apr 15, 2024 | Press Releases
– FDA acceptance of 4-week global registrational Phase 3 RECOVER-2 study — Two positive 4-week studies plus a 12-month long-term safety study have potential to support a New Drug Application (NDA) for brilaroxazine in schizophrenia –- Topline data...
Mar 28, 2024 | Press Releases
CUPERTINO, Calif., March 28, 2024 — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of...
